Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhi...

Full description

Saved in:
Bibliographic Details
Published inScience translational medicine Vol. 7; no. 291; p. 291ra96
Main Authors Lim, Yiting, Gondek, Lukasz, Li, Li, Wang, Qiuju, Ma, Hayley, Ma, Haley, Chang, Emily, Huso, David L, Foerster, Sarah, Marchionni, Luigi, McGovern, Karen, Watkins, David Neil, Peacock, Craig D, Levis, Mark, Smith, Bruce Douglas, Merchant, Akil A, Small, Donald, Matsui, William
Format Journal Article
LanguageEnglish
Published United States 10.06.2015
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhibition of other factors contributing to the malignant phenotype is required. We examined gene expression data sets as well as primary specimens and found that the expression of GLI2, a major effector of the Hedgehog (Hh) signaling pathway, was increased in FLT3-ITD compared to wild-type FLT3 AML. To examine the functional role of the Hh pathway, we studied mice in which Flt3-ITD expression results in an indolent myeloproliferative state and found that constitutive Hh signaling accelerated the development of AML by enhancing signal transducer and activator of transcription 5 (STAT5) signaling and the proliferation of bone marrow myeloid progenitors. Furthermore, combined FLT3 and Hh pathway inhibition limited leukemic growth in vitro and in vivo, and this approach may serve as a therapeutic strategy for FLT3-ITD AML.
ISSN:1946-6242
DOI:10.1126/scitranslmed.aaa5731